Financial Times: Big Pharma must lose its resistance to antibiotic research
Anjana Ahuja, science commentator

“…[T]he [U.K.’s Review on Antimicrobial Resistance] report’s unwritten message: that the curtain must come down on pure profiteering. The industry is being prompted to remember what corporate social responsibility stands for: a duty to shareholders accompanied by an obligation to serve the wider public good. This consideration has transformed the outlook for malaria and tuberculosis, once shunned as diseases of the poor but now at the heart of some vibrant, productive public-private partnerships. Profit cannot be the sole motive of an industry founded on making people better…” (5/17).

Wired: How Big Pharma Can Save Antibiotics From Superbugs
Jim O’Neill, chair of the Review on Antimicrobial Resistance

“…My hope is that China will seize the opportunity to lead the world against this global threat when it hosts the G20 in 2016 for the first time. … First we need to ensure there is a sustainable commercial market for antibiotics once they have come out of clinical trial. … A global AMR Innovation Fund of around $2 billion over five years would help boost funding for blue-sky research into drugs and diagnostics, and get more good ideas off the ground. In my view, big pharma should pay for this innovation fund … However, new drugs are not the whole solution: we shouldn’t fill up the bath without fixing the holes in it. We must balance the demand as well as the supply of drugs. … These are all important issues which my Review will consider and for which international agreement is required to achieve a lasting solution. The bottom line is: we can fix this” (5/15).